1. Home
  2. NIU vs IVVD Comparison

NIU vs IVVD Comparison

Compare NIU & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$2.03

Market Cap

200.8M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$0.85

Market Cap

201.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIU
IVVD
Founded
2014
2020
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.8M
201.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
NIU
IVVD
Price
$2.03
$0.85
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$3.50
$8.75
AVG Volume (30 Days)
224.5K
2.9M
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
$25.54
$61.57
Revenue Next Year
$17.70
$41.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$1.93
$0.49
52 Week High
$5.67
$3.07

Technical Indicators

Market Signals
Indicator
NIU
IVVD
Relative Strength Index (RSI) 34.52 62.91
Support Level N/A $0.73
Resistance Level $2.40 $1.01
Average True Range (ATR) 0.10 0.06
MACD -0.06 0.03
Stochastic Oscillator 6.19 96.95

Price Performance

Historical Comparison
NIU
IVVD

About NIU Niu Technologies

Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Share on Social Networks: